Skye Bioscience Downgraded to Nasdaq Capital Market Due to Equity Shortfall
SKYE sits 25% above its 52-week low of $0.566.
Summary
Nasdaq has approved Skye Bioscience's transfer to the Nasdaq Capital Market, effective today, due to the company's failure to meet the $10 million stockholders' equity requirement for the Global Market. This move follows the delisting notice received on May 15th for the same equity shortfall, confirming the company's financial struggles. Skye Bioscience also continues to face a separate compliance issue for its share price falling below the $1.00 minimum bid, with a deadline of September 14, 2026. This downgrade to a lower-tier market underscores the company's precarious financial health, as previously indicated by its Q1 2026 going concern warning. The company must now address the bid price deficiency to avoid further delisting threats.
At the time of this announcement, SKYE was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.9M. The 52-week trading range was $0.57 to $5.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.